Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AZD9496 Forms in Healthy Subjects
NCT02780713Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD9496 in breast cancer, sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration at Day 4, Area Under the Curve From Time Zero to Last Observation at Day 4 and 1 more. Started Jun 2016; status: completed.
02
Drugs
AZD9496
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02780713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780713.